The National Football League has signed its first-ever pharmaceutical partner in a multi-year deal with Switzerland-based ...

The RNA inhibitor reduces levels of oxidized phospholipids, which are presumed to promote atherosclerosis, by more than 93%.

In the trials, omalizumab and multi-allergen oral immunotherapy showed alike efficacy in protecting against food allergies, ...

Novartis has teamed up with the NFL in a multi-year partnership, marking the first such collaboration between the football ...

Novartis, a leading innovative medicines company, and the National Football League (NFL) announced an unprecedented partnership that names Novartis as the official first-in-category corporate ...

Today, Folia Health and Novartis Pharmaceuticals, Inc. proudly announce their collaboration on an innovative, at-home ...

The NFL have signed its first-ever pharmaceutical partner in a multi-year deal with Novartis to focus on the NFL’s health ...

The NFL has inked a multi-year deal with pharmaceutical giant Novartis, marking its first such partnership. This ...

The exclusive negotiating window for Visa, a 30-year NFL sponsor, to renew its deal with the league has expired, and the NFL ...

Under the terms of the agreement, Kyorin will receive $55m upfront and will be eligible for milestone payments of up to ...

Swiss pharmaceutical company Novartis has renewed its 15,865-square-foot office at Property & Building Corporation’s 10 ...

The third-place slot marked another return to form. Novo Nordisk’s Wegovy reclaimed the seat it held in December, backed by ...